Clinical Trial Update: A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety and activity of pegylated recombinant human arginase (BCT-100) in pediatric cancers; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Solid Tumor

Drugs mentioned

• Pegylated recombinant human arginase (BCT-100) (pegylated recombinant human arginase)

Snippet

Sponsor: University of Birmingham | Conditions: Cancer, Pediatric Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED